A Phase 1 Open-Label Dose-Escalating Study to Determine the Safety, and Tolerability of VT301 in Subjects With Mild-to-Moderate Alzheimer's Disease
Latest Information Update: 04 Aug 2023
At a glance
- Drugs VT 301 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors VT BIO
Most Recent Events
- 25 Aug 2021 New trial record